Lexaria Bioscience Corp.
LEXX
Price:
$2.28
Market Cap:
$39.79M
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectiv...[Read more]
Industry
Biotechnology
IPO Date
2021-01-12
Stock Exchange
NASDAQ
Ticker
LEXX
PE Ratio
[-5.18]
ROE
[-82.80%]
Current Ratio
[58.27]
Dividend Yield
[0%]
Enterprise Value
[31.48M]
Dividend History
The ROE as of November 2024 (TTM) for Lexaria Bioscience Corp. (LEXX) is -82.80%
According to Lexaria Bioscience Corp.’s latest financial reports and current stock price. The company's current ROE is -82.80%. This represents a change of 231.90% compared to the average of -24.95% of the last 4 quarters.
Lexaria Bioscience Corp. (LEXX) Historical ROE (quarterly & annually)
How has LEXX ROE performed in the past?
The mean historical ROE of Lexaria Bioscience Corp. over the last ten years is -177.85%. The current -82.80% ROE has changed -53.45% with respect to the historical average. Over the past ten years (40 quarters), LEXX's ROE was at its highest in in the February 2021 quarter at 3.43%. The ROE was at its lowest in in the May 2016 quarter at -213.79%.
Average
-177.85%
Median
-167.88%
Minimum
-456.60%
Maximum
-18.88%
Lexaria Bioscience Corp. (LEXX) ROE by Quarter and Year
Discovering the peaks and valleys of Lexaria Bioscience Corp. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 758.23%
Maximum Annual ROE = -18.88%
Minimum Annual Increase = -88.17%
Minimum Annual ROE = -456.60%
| Year | ROE | Change |
|---|---|---|
| 2023 | -218.94% | 139.41% |
| 2022 | -91.45% | 384.43% |
| 2021 | -18.88% | -88.17% |
| 2020 | -159.60% | -9.40% |
| 2019 | -176.16% | -36.24% |
| 2018 | -276.31% | 344.38% |
| 2017 | -62.18% | -86.38% |
| 2016 | -456.60% | 99.20% |
| 2015 | -229.22% | 157.11% |
| 2013 | -89.15% | 758.23% |
Lexaria Bioscience Corp. (LEXX) Average ROE
How has LEXX ROE performed in the past?
The current ROE of Lexaria Bioscience Corp. (LEXX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-109.76%
5-year avg
-133.01%
10-year avg
-177.85%
Lexaria Bioscience Corp. (LEXX) ROE vs. Peers
How is LEXX’s ROE compared to its peers?
Lexaria Bioscience Corp.’s ROE is greater than Revelation Biosciences, Inc. (-243.91%), greater than Zura Bio Limited (-35.45%), greater than Phio Pharmaceuticals Corp. (-142.68%), greater than ZyVersa Therapeutics, Inc. (-172.51%), greater than TransCode Therapeutics, Inc. (-597.47%), greater than Immix Biopharma, Inc. (-86.48%), less than CNS Pharmaceuticals, Inc. (428.91%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), greater than Sonnet BioTherapeutics Holdings, Inc. (-398.33%), less than SeaStar Medical Holding Corporation (323.08%), greater than Virios Therapeutics, Inc. (-130.35%), less than Biodexa Pharmaceuticals Plc (0%), greater than Oncorus, Inc. (-101.74%), greater than null (-130.61%),
| Company | ROE | Market cap |
|---|---|---|
| -243.91% | $3.19M | |
| -35.45% | $278.69M | |
| -142.68% | $2.76M | |
| -172.51% | $1.96M | |
| -597.47% | $8.89M | |
| -86.48% | $43.37M | |
| 428.91% | $3.98M | |
| 2.18% | $1.88K | |
| -173.56% | $50.04K | |
| -398.33% | $2.96M | |
| 323.08% | $12.30M | |
| -130.35% | $206.50K | |
| 0% | $3.30M | |
| -101.74% | $3.14M | |
| -130.61% | $0 |
Build a custom stock screener for Lexaria Bioscience Corp. (LEXX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lexaria Bioscience Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Lexaria Bioscience Corp. (LEXX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Lexaria Bioscience Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Lexaria Bioscience Corp.'s ROE?
How is the ROE calculated for Lexaria Bioscience Corp. (LEXX)?
What is the highest ROE for Lexaria Bioscience Corp. (LEXX)?
What is the 3-year average ROE for Lexaria Bioscience Corp. (LEXX)?
What is the 5-year average ROE for Lexaria Bioscience Corp. (LEXX)?
How does the current ROE for Lexaria Bioscience Corp. (LEXX) compare to its historical average?